Ann: AGM Chair's address and CEO's presentation, page-26

They certainly did.

My response below.

Thanksfor the response. I don’t need to talk with Cheryl.

Ijust want to express my disappointment that such a major announcement such asthe termination of a partnership that promised so much potential was hiddenaway in a figure within an AGM presentation.

Iknow you stated in your email and in announcements that there have not been any active clinical trials since 31July 2023, however, the partnership with Astrazeneca (as advertised in theAnnual report Aug 2024) was still a major attraction for any investor up untilit was communicated that the partnership had ended during an AGM where therewas to be votes on a remuneration report.

Iam sure if it were a positive development, this announcement would have beenmade as a standalone price sensitive ASX announcement.

Itis just disappointing that it looks like the smoke and mirrors have continuedeven after the appointment of the new CEO.